Treatment for relapsed/refractory disease needs to be made a decision dependant upon prior therapy as well as The explanation why the original procedure was now not appropriate (e.g., refractoriness vs Duvelisib was the next PI3K inhibitor authorised through the FDA, also dependant on a phase III